Am J Transplant, Volume 22, Suppl 3 Archives - Page 48 of 190 - ATC Abstracts

2022 American Transplant Congress
Attitudes Regarding COVID-19 Vaccine and Vaccine Hesitancy in an Inner-City Kidney Transplant Recipients (KTRs)
E. Bae, L. Wei, C. Canning, S. Martinez-Machado, J. Lee, L. Patel, M. Markell
SUNY Downstate Health Sciences University, Brooklyn, NY
*Purpose: KTRs comprise a high-risk group for COVID-19 infection due to comorbidities and immunosuppression. Studying how vaccination hesitancy in inner-city KTRs has changed since the…
2022 American Transplant Congress
Impact of the Second Year COVID-19 Pandemic on the U.S. Kidney Transplantation: Interrupted Time Series Analysis
E. Tantisattamo¹, N. Polpichai², P. Mutirangura³, M. Tanariyakul⁴
¹Division of Nephrology, Hypertension and Kidney Transplantation, Department of Medicine, University of California Irvine School of Medicine, Orange, CA, ²Faculty of Medicine Songklanagarin Hospital, Prince of Songkla University, Songkhla, Thailand, ³Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, ⁴Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
*Purpose: The number of kidney transplant (KT) was decreased since the COVID-19 pandemic; however, the magnitude of the pandemic on the number of U.S. KT…
2022 American Transplant Congress
No Difference in Graft Survival Among Low Socioeconomic Kidney Allograft Recipients
A. Desai¹, S. Akkina¹, K. Cmunt², D. Jain¹, R. Garcia-Roca³
¹Transplant Nephrology, Loyola University Medical Center, Maywood, IL, ²Gift Of Hope Community Foundation, Itasca, IL, ³Transplant Surgery, Loyola University Medical Center, Maywood, IL
*Purpose: Low socioeconomic status remains a barrier in access and equity in kidney transplantation with limited data assessing post-transplant outcomes. Alternative options to transplantation include…
2022 American Transplant Congress
Kidney Transplant Professionals’, Recipients’ and Caregivers’ Perspectives on the Use of Precision Medicine in Kidney Transplantation
F. Ballesteros Gallego¹, A. Affdal¹, M. Malo², R. Sapir-Pichhadze³, M. Fortin¹
¹CRCHUM, Montreal, QC, Canada, ²University of Montreal, Montreal, QC, Canada, ³McGill University, Montreal, QC, Canada
*Purpose: Kidney transplantation is the optimal treatment for end-stage kidney disease. However, antibody-mediated rejection can lead to graft loss. The use of Precision Medicine (PM)…
2022 American Transplant Congress
Variability of Serum Klotho and FGF-23 Levels During the First Two Years After Kidney Transplantation
T. Vazquez-Sanchez¹, M. Sanchez-Niño², P. Ruiz-Esteban¹, V. López¹, J. Delgado¹, A. Ortiz³, D. Hernández¹
¹Nephrology Department, Regional University Hospital (IBIMA), REDinREN (RD16/0009/0006), Malaga (España), Malaga, Spain, ²Nephrology Department, Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz, Universidad Autónoma de Madrid. REDINREN, Madrid, Spain, ³Nephrology Department, Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz, Universidad Autónoma de Madrid. REDINREN, Madrid, Spain, Madrid, Spain
*Purpose: Klotho is a protein produced in renal tubular cells with nephroprotective actions which acts as a co-receptor for phosphaturic factor FGF-23. The natural history…
2022 American Transplant Congress
Streamlining Donation Transplantation Communication Via HIPAA-compliant App
J. Piano, W. Liu
Transplant Connect, Los Angeles, CA
*Purpose: Communication across the donation transplantation ecosystem is fractured and ineffectual, often necessitating the use of unsecured methods such as texting in order to accomplish…
2022 American Transplant Congress
HLA-II Subclasses Behave Differently Between Themselves and Between Humans: Cues to Understand Alloreactivity
S. Beland, O. Desy, M. Marcoux, M. Thivierge, J. Desgagnes, S. A. De Serres
Transplantation Unit, Renal Division, University Health Center of Quebec, Faculty of Medicine, Universite Laval, Quebec, QC, Canada
*Purpose: De novo anti-HLA-II DSAs (dnDSA) are associated with antibody-mediated rejection. However, some patients with anti-HLA-II DSAs will not develop rejection, suggesting that the development…
2022 American Transplant Congress
Pegloticase Use in Renal Transplant Recipients with Gout: Findings from an Insurance Claims Database Study
C. A. Shadur¹, B. Marder², C. Vesel², B. LaMoreaux²
¹Iowa Kidney Physicians, Des Moines, IA, ²Horizon Therapeutics plc, Deerfield, IL
*Purpose: Kidney transplant (KT) recipients have high gout incidence due to reduced eGFR and medication use associated with hyperuricemia.1 Oral urate-lowering therapies in KT patients…
2022 American Transplant Congress
Sodium-Glucose Cotransporter 2 Inhibitors to Treat Diabetes Mellitus After Kidney Transplant
H. M. Brokmeier¹, S. B. Leung¹, A. Kukla², K. C. Mara³, P. Shah⁴, Y. Kudva⁴, G. K. Mour⁵, H. M. Wadei⁶, J. M. Hill⁷, M. D. Stegall⁸, A. Lemke¹
¹Pharmacy, Mayo Clinic, Rochester, MN, ²Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, ³Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN, ⁵Nephrology Transplant, Mayo Clinic, Phoenix, AZ, ⁶Nephrology, Mayo Clinic, Jacksonville, FL, ⁷Transplant, Mayo Clinic, Rochester, MN, ⁸Division of Transplant Surgery, Mayo Clinic, Rochester, MN
*Purpose: This study describes experience prescribing sodium-glucose cotransport 2 inhibitors (SGLT2i) after kidney transplant to evaluate safety and effectiveness.*Methods: This is a retrospective, institutional review…
2022 American Transplant Congress
Sirolimus Regimens After Kidney Transplantation: Role of Pre-Transplant Risk Factors in Modifying the Risk of Mortality in Adult Recipients
A. Santos¹, H. Ibrahim¹, M. A. Leghrouz¹, X. Wen²
¹University of Florida, Gainesville, FL, ²University of Rhode Island, Kinston, RI
*Purpose: We aimed to investigate the role of risk factors in modifying the association of sirolimus with mortality in kidney transplant (KT) recipients (KTRs).*Methods: Using…